HC Wainwright Boosts DiaMedica Therapeutics (NASDAQ:DMAC) Price Target to $10.00

DiaMedica Therapeutics (NASDAQ:DMAC) had its target price lifted by HC Wainwright from $7.00 to $10.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics Trading Down 3.1 %

Shares of NASDAQ DMAC opened at $4.98 on Wednesday. DiaMedica Therapeutics has a 1 year low of $2.14 and a 1 year high of $6.82. The firm’s 50-day moving average is $5.93 and its 200-day moving average is $5.11. The firm has a market capitalization of $212.95 million, a PE ratio of -8.89 and a beta of 1.52.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). As a group, equities research analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DMAC. Point72 Asia Singapore Pte. Ltd. bought a new position in DiaMedica Therapeutics during the third quarter worth about $40,000. Balyasny Asset Management L.P. bought a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $79,000. Y Intercept Hong Kong Ltd bought a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $81,000. Raymond James Financial Inc. acquired a new position in DiaMedica Therapeutics during the fourth quarter valued at approximately $83,000. Finally, Bank of Montreal Can bought a new stake in DiaMedica Therapeutics in the fourth quarter valued at approximately $84,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.